Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/dom.12654 http://scihub22266oqcxt.onion/10.1111/dom.12654 C4850750!4850750!26936519     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Diabetes+Obes+Metab 2016 ; 18 (6): 590-7 Nephropedia Template TP {{tp|p=26936519|t=2016. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin?angiotensin blockers |pdf=|usr=}}{{26936519}} gab.com Text Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin angiotensin blockers JO: Diabetes Obes Metab http://www.kidney.de/pget.php?&tw=1&pmid=26936519 #FOAvip Aims: To characterize the effect of dapagliflozin on albuminuria and estimated glomerular filtration rate (eGFR) and to determine whether effects on albuminuria were mediated through changes in glycated haemoblogin (HbA1c), systolic blood pressure (SBP), body weight or eGFR. Methods: We conducted a post hoc analysis of data pooled from two phase III clinical trials in hypertensive patients with type 2 diabetes (T2DM) on stable angiotensin?converting enzyme inhibitor or angiotensin receptor blocker therapy, randomly assigned to dapagliflozin 10 mg/day or matched placebo. This analysis included only patients with microalbuminuria or macroalbuminuria at baseline. Results: Patients were randomized to receive dapagliflozin 10 mg (n = 167) or placebo (n = 189). Dapagliflozin resulted in greater 12?week reductions in albuminuria compared with placebo: ?33.2% [95% confidence interval (CI) ?45.4, ?18.2]. The reduction in albuminuria was also present after adjusting for age, sex and changes in HbA1c, SBP, body weight and eGFR: ?23.5% (95% CI ?37.6, ?6.3). There was a decrease in eGFR with dapagliflozin versus placebo that was readily reversed 1 week after last dose. No serious renal?related adverse events were observed in any group. Conclusions: Dapagliflozin was effective in lowering albuminuria in patients with T2DM and hypertension using renin?angiotensin system blockade therapy. Reductions in albuminuria were still present after adjusting for changes in HbA1c, SBP, body weight and eGFR. Dapagliflozin?induced improvements in glycaemic control and reductions in SBP, coupled with other potentially beneficial renal effects, may lead to a reduced long?term renal and cardiovascular risk. Twit Text FOAVip Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin angiotensin blockers ????Diabetes Obes Metab http://www.kidney.de/pget.php?&tw=1&pmid=26936519 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26936519 #FOAvip English Wikipedia <ref>{{Cite pmid|26936519}}</ref> Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin?angiotensin blockers #MMPMID26936519 Heerspink HJL; Johnsson E; Gause?Nilsson I; Cain VA; Sjöström CD Diabetes Obes Metab 2016[Apr]; 18 (6): 590-7 PMID26936519show ga Aims: To characterize the effect of dapagliflozin on albuminuria and estimated glomerular filtration rate (eGFR) and to determine whether effects on albuminuria were mediated through changes in glycated haemoblogin (HbA1c), systolic blood pressure (SBP), body weight or eGFR. Methods: We conducted a post hoc analysis of data pooled from two phase III clinical trials in hypertensive patients with type 2 diabetes (T2DM) on stable angiotensin?converting enzyme inhibitor or angiotensin receptor blocker therapy, randomly assigned to dapagliflozin 10 mg/day or matched placebo. This analysis included only patients with microalbuminuria or macroalbuminuria at baseline. Results: Patients were randomized to receive dapagliflozin 10 mg (n = 167) or placebo (n = 189). Dapagliflozin resulted in greater 12?week reductions in albuminuria compared with placebo: ?33.2% [95% confidence interval (CI) ?45.4, ?18.2]. The reduction in albuminuria was also present after adjusting for age, sex and changes in HbA1c, SBP, body weight and eGFR: ?23.5% (95% CI ?37.6, ?6.3). There was a decrease in eGFR with dapagliflozin versus placebo that was readily reversed 1 week after last dose. No serious renal?related adverse events were observed in any group. Conclusions: Dapagliflozin was effective in lowering albuminuria in patients with T2DM and hypertension using renin?angiotensin system blockade therapy. Reductions in albuminuria were still present after adjusting for changes in HbA1c, SBP, body weight and eGFR. Dapagliflozin?induced improvements in glycaemic control and reductions in SBP, coupled with other potentially beneficial renal effects, may lead to a reduced long?term renal and cardiovascular risk. äDapagliflozin reduces albuminuria in patients with diabetes and hypert(epmc).pdf DeepDyve Pubget Overpricing